Esperion Therapeutics has announced that bempedoic acid has been included in the 2025 Focused Update of the 2019 European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias. This update marks bempedoic acid as the only non-statin therapy recommended for lowering LDL-C and reducing cardiovascular risk, receiving a Level 1a recommendation.
This recognition from leading cardiovascular authorities underscores the clinical efficacy of bempedoic acid, particularly for patients who cannot tolerate statin therapy. The guidelines emphasize the importance of aggressive LDL-C management, advocating for non-statin therapies to be considered in combination with statins or as monotherapy where appropriate. As Esperion expands its market presence, the endorsement from ESC/EAS is expected to influence upcoming US cholesterol treatment guidelines.
Esperion’s strategic focus on developing innovative lipid-lowering therapies positions it to meet the evolving needs of healthcare providers and patients. With the introduction of combination therapies like NEXLIZET and NEXLETOL, Esperion aims to enhance treatment adherence and optimize patient outcomes in managing dyslipidaemias.
